Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group.
Bustoros M, Kastritis E, Sklavenitis-Pistofidis R, Liu CJ, Hornburg K, Kanellias N, Kim G, Liu D, Gavriatopoulou M, Marinac CR, Roussou M, Migkou M, Noonan K, Reyes K, Rivotto B, Neuse CJ, Ziogas DC, Laubach J, Terpos E, Anderson KC, Richardson PG, Ghobrial IM, Dimopoulos MA. Bustoros M, et al. Among authors: reyes k. Am J Hematol. 2019 May;94(5):E146-E149. doi: 10.1002/ajh.25441. Epub 2019 Mar 6. Am J Hematol. 2019. PMID: 30773670 Free article. Clinical Trial. No abstract available.
Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients.
Sklavenitis-Pistofidis R, Capelletti M, Liu CJ, Reidy M, Zavidij O, Huynh D, Henrick P, Savell A, Reyes K, Rivotto B, Bustoros M, Perilla-Glen A, Trippa L, Castillo JJ, Treon SP, Ghobrial IM. Sklavenitis-Pistofidis R, et al. Among authors: reyes k. Blood. 2018 Dec 13;132(24):2608-2612. doi: 10.1182/blood-2018-07-863241. Epub 2018 Oct 26. Blood. 2018. PMID: 30366921 Free PMC article. Clinical Trial. No abstract available.
Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia.
Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, Liu CJ, Kastritis E, Zanwar S, Fell G, Abeykoon JP, Hornburg K, Neuse CJ, Marinac CR, Liu D, Soiffer J, Gavriatopoulou M, Boehner C, Cappuccio JM, Dumke H, Reyes K, Soiffer RJ, Kyle RA, Treon SP, Castillo JJ, Dimopoulos MA, Ansell SM, Trippa L, Ghobrial IM. Bustoros M, et al. Among authors: reyes k. J Clin Oncol. 2019 Jun 1;37(16):1403-1411. doi: 10.1200/JCO.19.00394. Epub 2019 Apr 16. J Clin Oncol. 2019. PMID: 30990729 Free PMC article.
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma.
Ghobrial IM, Liu CJ, Zavidij O, Azab AK, Baz R, Laubach JP, Mishima Y, Armand P, Munshi NC, Basile F, Constantine M, Vredenburgh J, Boruchov A, Crilley P, Henrick PM, Hornburg KTV, Leblebjian H, Chuma S, Reyes K, Noonan K, Warren D, Schlossman R, Paba-Prada C, Anderson KC, Weller E, Trippa L, Shain K, Richardson PG. Ghobrial IM, et al. Among authors: reyes k. Am J Hematol. 2019 Nov;94(11):1244-1253. doi: 10.1002/ajh.25627. Epub 2019 Oct 4. Am J Hematol. 2019. PMID: 31456261 Free article. Clinical Trial.
A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma.
Ghobrial IM, Liu CJ, Redd RA, Perez RP, Baz R, Zavidij O, Sklavenitis-Pistofidis R, Richardson PG, Anderson KC, Laubach J, Henrick P, Savell A, Reyes K, Hornburg K, Chuma S, Sabbatini P, Robbins MD, Becker PS. Ghobrial IM, et al. Among authors: reyes k. Clin Cancer Res. 2020 Jan 15;26(2):344-353. doi: 10.1158/1078-0432.CCR-19-0647. Epub 2019 Oct 31. Clin Cancer Res. 2020. PMID: 31672767 Clinical Trial.
242 results